In the Boardroom
Refine Search
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Pharmaceutical
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
French cancer vaccine focused biotech Oncovita has appointed Dr Stéphane Altaba as its new chief executive (CEO). 9 October 2024
Biotechnology
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Biotechnology
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Pharmaceutical
US pharma giant Pfizer (NYSE: PFE) has announced that John McGinley has been appointed UK managing director and country president. 7 October 2024
Pharmaceutical
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Pharmaceutical
US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. 18 February 2014
Biotechnology
US biotech firm Biogen Idec has announced today that chairman of the board William Young, known as Bill, will retire from the company’s Board of Directors, effective at the company’s 2014 annual meeting of stockholders. 17 February 2014
Pharmaceutical
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Graham Hetherington, chief financial officer, has decided to step down from the company. 13 February 2014
Biotechnology
Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president and general counsel. 13 February 2014
Pharmaceutical
European quotas for immigration could have an effect on the pharmaceutical industry, according to recruitment experts. 11 February 2014
Biotechnology
Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive chairman of the Board of Directors, effective March 1. 11 February 2014
Biotechnology
A global survey of chief executives has revealed the priorities and concerns of pharmaceutical and life sciences CEOs. 7 February 2014
Pharmaceutical
The founder of Douglas Pharmaceuticals, Sir Graeme Douglas, has announced his retirement as the company’s managing director, effective February 1. 4 February 2014
Generics
US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of its global strategic business structure to maximize the company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. 1 February 2014
Pharmaceutical
E. Merck KG, which combines the financial interests of the Merck family and is general partner of Germany’s Merck KGaA (MRK: DE) with an interest of 70%, announced at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG. 28 January 2014
Pharmaceutical
Karolinska Development has announced that Christian Tange has accepted the role of Chief Financial Officer. 28 January 2014
Biotechnology
US biotech major Gilead Sciences (Nasdaq: GILD) has announced several promotions within the company's senior management team. 28 January 2014
Biotechnology
US biotech firm Chelsea Therapeutics’ (Nasdaq: CHTP) has named Joseph Oliveto as president and chief executive officer and a member of the company's board of directors, effective January 22. 27 January 2014
Pharmaceutical
Privately-held US drugmaker Purdue Pharma has appointed Mark Timney as president and chief executive. He succeeds John Stewart, who has retired from Purdue. 27 January 2014
Pharmaceutical
Chief financial officer of Germany’s Merck KGaA (MRK: DE) Matthias Zachert has been appointed as chief executive of Lanxess. 27 January 2014
Pharmaceutical
Ireland-headquartered drugmaker Shire (LSE: SHP) has announced that Susan Kilsby will become non-executive chairman, replacing Matthew Emmens who is retiring at the company’s AGM on April 29. 23 January 2014
Pharmaceutical
French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision to set up its own oncology team to commercialize Somatuline Depot (lanreotide) in neuroendocrine tumors (NETs) in the USA. 22 January 2014
Pharmaceutical
Swedish drug development company Dilaforette has named Christina Herder as its new chief executive. 22 January 2014
Pharmaceutical
Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its CNS Drug Discovery Unit, Pharmaceutical Research Division. 15 January 2014
Generics
US generics and specialty drugmaker Actavis has announced an updated business structure for its US Specialty Brands business designed to maximize the company's newly-strengthened position in key therapeutic areas and position it for continued long-term growth. 14 January 2014
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze